Novartis AG
NVSHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Novartis AG focuses on Drug Manufacturers - General services and products. Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. With a market capitalization of $286.54B, it sits in mega-cap territory. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
Market Cap
$286.54B
Beta
0.49
P/E (TTM)
21.51
P/E (Fwd)
15.09
EPS (TTM)
$6.98
EPS (Fwd)
$9.95
ROE
34.9%
ROA
10.5%
Cash
$6.89B
Total Debt
$47.00B
Free CF
$12.02B
52W Change
28.7%
Annual Financials
Cash vs Debt
The company holds $6.89B in cash, though total debt stands at $47.00B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $12.02B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 34.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.5% further supports the picture of efficient asset utilization. Revenue has grown from $43.46B (2022) to $56.67B (2025), reflecting a 30% increase over the period.
NVS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NVS.